Leveraging Experience From Active TB Drug-Safety Monitoring and Management for Monitoring Active Antiretroviral Toxicity.

Abstract

<h3>Key Messages</h3> The introduction of novel medicines and regimens for antiretroviral (ARV) and TB treatment requires comprehensive surveillance systems for adverse events and adverse drug reactions. Many TB programs have introduced and institutionalized active drug safety monitoring and management (aDSM) platforms for drug-resistant TB. Because HIV programs must develop active ARV toxicity monitoring systems to ensure safe global scale-up of newer regimens, such as tenofovir-lamivudine-dolutegravir, we propose building on existing aDSM infrastructure to actively monitor ARV regimens as a synergistic TB/HIV collaborative activity and to narrow active toxicity monitoring gaps.